Business
Codexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USA
--Proprietary technology being developed to address sustainability and scalability challenges of oligonucleotide manufacturing-- REDWOOD CITY, Calif., May 10,
About this update from Codexis, Inc.
[{"type":"text","content":"--Proprietary technology being developed to address sustainability and scalability challenges of oligonucleotide manufacturing--\nREDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the unveiling of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, a proprietary new synthesis platform being developed for manufacturing RNA oligonucleotide therapeutics at scale. The ECO Synthesis™ technology was unveiled during a pre-conference workshop at the TIDES USA annual meeting, being held May 7-10, 2023, in San Diego, CA. Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction in recent years with the growing number of messenger RNA (mRNA) vaccines and small interfering RNA (siRNA) product candidates advancing in clinical studies. However, large-scale production faces complex challenges in nucleic acids quality and quantity, as well as overall economics. By replacing phosphoramidite chemistry with enzymatic methods, Codexis’ proprietary ECO Synthesis™ technology is specifically engineered to overcome these difficulties to enable scalable and sustainable manufacturing. “At TIDES, we were pleased to introduce our ECO Synthesis™ platform, an enzymatic solution with the potential to enable truly scalable RNAi therapeutics production,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis. “As RNA-based therapeutics are applied to larger disease indications, we believe the current route of chemical synthesis will rapidly become unsustainable, and our customers have already voiced the need for an enzymatic option to manufacture siRNA. Between our long history of engineering increasingly complex enzymes for Pharmaceutical Manufacturing and our existing base of relevant customer relationships, we are uniquely positioned for success in this emerging market. We are well on our way toward developing the suite of enzymes necessary for the full platform, and we look forward to reporting further progress at scientific meetings later this year.” The TIDES presentation slides are available on the ‘News & Events’ page within the Investor Relations section of the Codexis website at https://www.codexis.com/investors/news-events; a video recording of the ECO Synthesis™ portion of the TIDES presentation will b...